A T van der Ploeg
Overview
Explore the profile of A T van der Ploeg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van den Dorpel J, Mackenbach M, Dremmen M, van der Vlugt W, Rizopoulos D, van Doorn P, et al.
J Inherit Metab Dis
. 2024 Apr;
47(4):716-730.
PMID: 38584574
The aim of this longitudinal cohort study, is to provide more insight into the pattern of brain abnormalities, and possible consequences for cognitive functioning, in patients with classic infantile Pompe...
2.
Scheffers L, Somers O, Dulfer K, Dieleman G, Walet S, van der Giessen L, et al.
J Inherit Metab Dis
. 2023 Apr;
46(4):605-617.
PMID: 37002894
Exercise has proven to be an effective adjuvant treatment to enzyme replacement therapy (ERT) in mildly affected adult Pompe patients. The aim of this study was to investigate the effects...
3.
Scheffers L, Kok R, van den Berg L, van den Hout J, Boersma E, van Capelle C, et al.
Int J Cardiol
. 2023 Mar;
380:65-71.
PMID: 36893858
Objective: Patients with classic infantile Pompe disease are born with a hypertrophic cardiomyopathy, which resolves after treatment with Enzyme replacement therapy (ERT). We aimed to assess potential deterioration of cardiac...
4.
Ismailova G, Mackenbach M, van den Hout J, van der Ploeg A, Brusse E, Wagenmakers M
Orphanet J Rare Dis
. 2022 Mar;
17(1):102.
PMID: 35246221
Introduction: Patients with Glycogen Storage Disease type II (GSDII), an inheritable metabolic myopathy also known as Pompe disease, are considered to be at risk for severe COVID-19 due to a...
5.
Schaefers J, van der Giessen L, Klees C, Jacobs E, Sieverdink S, Dremmen M, et al.
Orphanet J Rare Dis
. 2021 May;
16(1):221.
PMID: 33990214
Background: Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa is now available...
6.
Molema F, Haijes H, Janssen M, Bosch A, van Spronsen F, Mulder M, et al.
Clin Nutr
. 2021 Jan;
40(5):3622-3630.
PMID: 33451859
Background And Objective: Methylmalonic acidemia (MMA) and propionic acidemia (PA) are inborn errors of metabolism. While survival of MMA and PA patients has improved in recent decades, long-term outcome is...
7.
van Kooten H, Roelen C, Brusse E, van der Beek N, Michels M, van der Ploeg A, et al.
Neuromuscul Disord
. 2021 Jan;
31(2):79-90.
PMID: 33386209
Pompe disease is a rare inherited metabolic and neuromuscular disorder, presenting as a spectrum, with the classic infantile form on one end and the more slowly progressive non-classic form on...
8.
van den Dorpel J, Poelman E, Harlaar L, van Kooten H, van der Giessen L, van Doorn P, et al.
Orphanet J Rare Dis
. 2020 Sep;
15(1):247.
PMID: 32928284
Background: Enzyme replacement therapy (ERT; alglucosidase alfa) has improved the prospects for patients with classic infantile Pompe disease considerably. However, over time we noticed that many of these children exhibit...
9.
van Kooten H, Harlaar L, van der Beek N, van Doorn P, van der Ploeg A, Brusse E
Neuromuscul Disord
. 2020 Jan;
30(1):59-66.
PMID: 31911071
Enzyme replacement therapy for Pompe disease received market authorization in 2006. To implement this costly treatment in the Netherlands in the most sensible way, a multidisciplinary expert committee was installed....
10.
Poelman E, Hoogeveen-Westerveld M, van den Hout J, Bredius R, Lankester A, Driessen G, et al.
Orphanet J Rare Dis
. 2019 Mar;
14(1):71.
PMID: 30902109
Purpose: To evaluate whether immunomodulation can eliminate high sustained antibody levels, and thereby improve clinical outcome in classic infantile Pompe patients receiving enzyme replacement therapy (ERT) with recombinant human alpha-glucosidase...